Savara Inc Defined Contribution Plan, Cost
Savara Inc (SVRA) reported Defined Contribution Plan, Cost of $242.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2017-03-06
- Savara Inc defined contribution plan, cost for fiscal 2016 was $242.00K, a 1.63% decline from fiscal 2015.
- Savara Inc defined contribution plan, cost for fiscal 2015 was $246.00K, a 16.04% increase from fiscal 2014.
- Savara Inc defined contribution plan, cost for fiscal 2014 was $212.00K, a 16.48% increase from fiscal 2013.
- Savara Inc defined contribution plan, cost for fiscal 2013 was $182.00K, a 11.54% increase from fiscal 2012.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2016-12-31 | $242.00K 10-K · filed 2017-03-06 | |
| 2015-12-31 | $246.00K 10-K · filed 2017-03-06 | |
| 2014-12-31 | $212.00K 10-K · filed 2017-03-06 | |
| 2013-12-31 | $182.00K 10-K · filed 2015-03-24 | $182.42K 10-K · filed 2014-03-26 |
| 2012-12-31 | $163.17K 10-K · filed 2014-03-26 | |
| 2011-12-31 | $87.79K 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |